• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$44.28 $0.04 (0.09%)

REAL-TIME: Last trade at

GlaxoSmithKline

NYSE:GSK

GlaxoSmithKline Buys 1.8 Million Own Shares To Hold In Treasury

RBS Launches Process To Replace Hoare Govett As Corporate Broker-Report

Is This Dow Heavyweight a Value Trap?

Abbott Wants To Extract More From Humira While Pfizer Slogs Along With Lipitor

The Fool's Guide to Buying U.K. Retail Bonds

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2

Human Genome Shareholders Should Not Get Greedy

GlaxoSmithKline Buys For Treasury 1.8 Million Shares

GlaxoSmithKline: CHMP Recommends Authorization For Pazopanib

Johnson & Johnson: An Uncommon Opportunity

Best of the Blogs, Biotech: Is an Anti-Obesity Drug Finally in Sight?

GlaxoSmithKline Buys Back 1.8 Million Own Shares To Hold In Treasury

Healthcare Dogs Stay Steady In April

Finding a Pathway to Approval

GlaxoSmithKline Buys Back 1.8 Million Shares For Treasury

Glaxo Amends Offer To Address HGS Shareholder Rights Plan

Top International Dividend Stocks - May 2012 - Danger Ahead!

Lilly's GLP-1 Agonist Delivers - Analyst Blog

Top Paying Dividend Stocks By Industry

Buffett and Woodford Agree on This One!

Roche Drugs To Be Key Focus At Upcoming US Cancer Meeting ASCO

GlaxoSmithKline Buys Back 1.8 Million Shares For Treasury

Auxilium-Glaxo to Drive Testim Sales - Analyst Blog

Auxilium To Promote Testosterone Gel With Glaxo; Raises View

20 Giants for a 6% Dividend Yield

GlaxoSmithKline Buys Back 1.8 Million Shares For Treasury

GlaxoSmithKline Buys Back 1.6 Million Shares

Glaxo Fails to Impress HGSI - Analyst Blog

Glaxo Hikes Stake in Theravance - Analyst Blog

Human Genome Looks to Anyone but GlaxoSmithKline

UPDATE: Human Genome Adopts Poison Pill With 15% Trigger To Deter Glaxo

Why U.K. Bonds Are for Losers

ADR Report: Shares Lower As Euro-Zone Worries Loom

GlaxoSmithKline Buys Back 1.2 Million Shares

GlaxoSmithKline Completes Acquisition Of 10 Million Theravance Shares

Glaxo Set to Acquire Cellzome - Analyst Blog

Drug Fails: At Least It's Approved Already

Make Money in Hefty Global Dividends the Easy Way

Pfizer, Johnson & Johnson, Ariad, and Medivation in Spotlight at Cancer Meeting

Big Changes To Buffett & Berkshire Hathaway Stock Holdings, A to Z

See More Articles...